@entity479 Use and Infectious Complication in Peritoneal Dialysis After XXXX .

@entity1 @entity8 @entity230 @entity298 @entity479
BACKGROUND: @entity298 ( @entity298 ) is one potential treatment option for @entity1 starting dialysis after graft loss (DAGL). However, the infectious outcomes and their associations with @entity479 use remain undetermined in these @entity1 . METHODS: A total of 41 DAGL @entity1 undergoing @entity298 were recruited. The @entity1 were divided into low- and high-dose @entity479 groups according to the median level. Additionally, they were categorized into tapering and nontapering groups, for which the tapering regimen was defined as the withdrawal of @entity230 within 1 year after starting @entity298 . Primary outcomes, such as @entity298 and exit site infection (ESI), were compared between DAGL and 712 @entity8 ( @entity8 ) @entity1 . RESULTS: The overall risk of @entity298 was similar between the @entity8 and DAGL groups. However, when the DAGL group was stratified by the @entity479 variable, the risk was higher in the high-dose or nontapering @entity479 groups than in the @entity8 or counterpart @entity479 groups. The DAGL group had a higher risk of ESI than the @entity8 group, irrespective of @entity479 dose. When the analysis was stratified by tapering regimen, the difference in ESI risks was seen only in the nontapering group and the @entity8 group; the tapering group had a similar risk of ESI as that of the @entity8 group. CONCLUSIONS: The present study first addresses the risks of @entity298 and ESI together and then raises awareness of the high risk that should be considered after using high-dose @entity230 or the nontapering regimen in the DAGL @entity1 .
